

PET Imaging of Inflammation and Lipid Lowering Study

NCT04073797

Status	RECRUITING
Phase	Not Applicable
Sponsor	University of Cambridge
Enrollment	63 participants

Key Eligibility Criteria

Inclusion (6)

- Male or female participants >18 years old
 - Able to give written, informed consent and to lie flat
 - Have primary hypercholesterolaemia (non-familial or definite or possible heterozygous familial hypercholesterolaemia (HeFH) based on clinical criteria) or mixed dyslipidaemia, and
 - History of CVD (acute coronary syndrome, coronary or other revascularisation procedures, coronary heart disease, ischaemic stroke, or peripheral arterial disease) and elevated LDL cholesterol ≥ 2.6 despite maximum tolerated statins with or without other lipid lowering therapies (see NICE TA 733), and
 - Lipid lowering therapy unchanged for at least 6 weeks prior to screening, and
- ... and 1 more (see full listing online)

Exclusion (14)

- Women of childbearing potential not using adequate contraception
 - Contra-indication to MRI scanning
 - Statin-associated myositis or liver function abnormality
 - Already taking inclisiran or colchicine
 - Sensitivity and/or contraindication to inclisiran or colchicine. Contraindications to colchicine include severe hepatic or renal impairment, blood disorders, and patients with renal or hepatic impairment who are taking a P-gp inhibitor or a strong CYP3A4 inhibitor
- ... and 9 more (see full listing online)

Locations (1 total)

University of Cambridge, Cambridge, United Kingdom